Amgen Beats Expectations for Fourth Quarter
Amgen Inc. beat Wall Street estimates in the fourth quarter, as sales from newer drugs such as migraine medication Aimovig offset lower revenue from older, off-patent medications.
Amgen Inc. beat Wall Street estimates in the fourth quarter, as sales from newer drugs such as migraine medication Aimovig offset lower revenue from older, off-patent medications.